Scientist II, DMPK at Entrada Therapeutics
Boston, MA
About the Job
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Our Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others.
Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. We have also partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families.
The Perfect Addition to Our TeamYou are a highly motivated, collaborative, and innovative Drug Metabolism and Pharmacokinetics scientist with experience contributing to preclinical DMPK activities. You have diverse experience across both small and large molecules and are looking to apply your hands on experience designing, analyzing, and interpreting data from preclinical in vitro and in vivo studies. You are an exceptional communicator and a natural collaborator who is excited about the opportunity to contribute to this function and work closely with cross functional leaders.
The OpportunityThe Scientist II, DMPK will serve as a primary member of the DMPK team to help execute on the DMPK strategy for our organization. They will have the opportunity to partner on, manage, and execute DMPK deliverables for programs in our pipeline. Reporting into the Senior Scientific Director, they will be responsible for analyzing, interpreting, and authoring/reviewing ADME and PK/PD reports. The ideal candidate will drive results both internally and externally to contribute to scientific publications and regulatory submissions.
Responsibilities- Manage assigned PK- and ADME-related efforts for designated program(s).
- Communicate and present relevant information across all areas of the organization.
- Partner closely with PK/TK, PK/PD, and ADME CROs.
- Author and review PK/TK, PK/PD, and ADME reports.
- Review associated reports, including clinical, toxicology, pharmacology, and bioanalysis.
- Collaborate with clinical teams including pharmacology, biomarkers, development, and operations and non-clinical development teams including toxicology and bioanalysis.
- Collaborate with discovery teams to guide future programs and better understand mechanisms of action.
At Entrada, our passion for science, our devotion to patients and our values drives our behavior:
- Humanity - We genuinely care about patients and about one another.
- Tenacity - We are relentless and persistent in the pursuit of developing therapies for patients.
- Creativity - We are creative problem solvers.
- Collaboration - We are more than the sum of our parts.
- Curiosity - We have a growth mindset and push conventional thought and theory.
To thrive on our team, you will need to come with:
- PhD in pharmacology or similar field with 2+ years of DMPK experience in an industry setting or a MS with 7+ years of relevant experience.
- Experience and working knowledge of pharmacokinetics, pharmacodynamics, drug metabolism, transporters and permeability, bioanalysis, or in-life PK studies.
- Ability to troubleshoot based upon raw data in partnership with CROs.
- Additional experience with other aspects of ADME, bioanalytical techniques, PK/PD, toxicokinetics, pre-clinical PK/PD modeling, and translational biology are a plus.
- Prior experience with oligonucleotide-based modalities is a plus.
- Experience with authoring and reviewing DMPK-related reports is preferred.#LI-Hybrid #LI-JF1
By becoming a team member here at Entrada, you’ll have access to competitive health, dental, and vision coverage, as well as life insurance, and short term and long-term disability insurance. We value work life balance, you'll benefit from discretionary time off, paternity leave, and an excellent 401(k) package. We also offer a generous transportation stipend to commute as you wish. Our location in the vibrant and growing Seaport District is close to all the best that the city of Boston has to offer.
Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law.
Third Party Staffing AgenciesEntrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes.
Privacy StatementEntrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement here to understand how and when your data is being used.